Jean-Baptiste Pinaquy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jean-Baptiste Pinaquy has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Charles Cazanave
Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Bordeaux, Groupe Hospitalier Pellegrin, Bordeaux, F-33000, France
4 shared publications- Sabine Pereyre
Bacteriology Department, National Reference Center for bacterial sexually transmitted infections, CHU de Bordeaux
4 shared publications Laurent Stecken
Anaesthetics Department, University Hospital of Bordeaux, Bordeaux, France
3 shared publicationsPhilippe Fernandez
CHU Bordeaux, France
3 shared publications- Xavier Berard
Department of Vascular Surgery, Bordeaux University Hospital, Bordeaux, France
3 shared publications Bruno Lapuyade
Service de Radiologie et d’Imagerie Diagnostique et Interventionnelle
2 shared publications
Latest Publications
- 21 October 2022
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 103 (11) , 563-565
Serous cystadenoma mimicking cystic pancreatic neuroendocrine tumor on 68Ga-DOTATOC PET/CT
- 21 October 2022
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 103 (11) , 563-565
Serous cystadenoma mimicking cystic pancreatic neuroendocrine tumor on 68Ga-DOTATOC PET/CT
- 8 September 2021
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 46 (12) , 958-964
Key Role of Personalized Dosimetry in Dose Adjustment for Selective Internal Radiotherapy
Purpose: Selective internal radiotherapy with 90Y microspheres is widely used for the treatment of patients with liver cancer. A dosimetric analysis using the dosimetry software Simplicit90y (Boston Scientific, Natick, MA) was conducted to define doses to the tumor and healthy liver, and to determine a threshold tumor dose that could predict progression-free survival. Methods: Patients experiencing hepatocellular carcinoma and treated with 90Y-labeled resin microspheres were included in a retrospective study. The time-to-progression of the target lesions (TTPLs) and overall survival (OS) were evaluated using Kaplan-Meier tests, and this comparison was based on a log-rank test. Results: Twenty-four procedures for patients with portal vein thrombosis were realized. Median follow-up was 16 months. A threshold tumor dose of 125 Gy was determined with a sensitivity of 89% and a specificity of 100%. For patients with a tumor dose of less than 125 Gy, the median OS was 7.5 months (95% confidence interval [CI], 5–14 months) and the TTPL was 3 months (95% CI, 2–6 months) versus 33 months (95% CI, 22–39 months) and 23 months (95% CI, 7–38 months), respectively, for those with a tumor dose of 125 Gy or more (P = 0.002 and P = 0.0004). Conclusions: Personalized dosimetry based on 99mTc-MAA SPECT/CT is predictive of TTPL and OS in patients with hepatocellular carcinoma. Customized dosimetry software is essential to optimize treatment planning.
- 8 September 2021
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 46 (12) , 958-964
Key Role of Personalized Dosimetry in Dose Adjustment for Selective Internal Radiotherapy
Purpose: Selective internal radiotherapy with 90Y microspheres is widely used for the treatment of patients with liver cancer. A dosimetric analysis using the dosimetry software Simplicit90y (Boston Scientific, Natick, MA) was conducted to define doses to the tumor and healthy liver, and to determine a threshold tumor dose that could predict progression-free survival. Methods: Patients experiencing hepatocellular carcinoma and treated with 90Y-labeled resin microspheres were included in a retrospective study. The time-to-progression of the target lesions (TTPLs) and overall survival (OS) were evaluated using Kaplan-Meier tests, and this comparison was based on a log-rank test. Results: Twenty-four procedures for patients with portal vein thrombosis were realized. Median follow-up was 16 months. A threshold tumor dose of 125 Gy was determined with a sensitivity of 89% and a specificity of 100%. For patients with a tumor dose of less than 125 Gy, the median OS was 7.5 months (95% confidence interval [CI], 5–14 months) and the TTPL was 3 months (95% CI, 2–6 months) versus 33 months (95% CI, 22–39 months) and 23 months (95% CI, 7–38 months), respectively, for those with a tumor dose of 125 Gy or more (P = 0.002 and P = 0.0004). Conclusions: Personalized dosimetry based on 99mTc-MAA SPECT/CT is predictive of TTPL and OS in patients with hepatocellular carcinoma. Customized dosimetry software is essential to optimize treatment planning.
- Open Access
- 1 June 2021
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 14, 2397-2401
An Infected Arterial Aneurysm and a Dog Bite: Think at Capnocytophaga canimorsus!
We describe the fourth cases of arterial aneurysm consecutive to Capnocytophaga canimorsus infection in a 77-year-old man. The infection occurred after a dog bite. He presented fever. The thoracic-abdominal computed tomography angiography revealed aneurysms on the abdominal aorta, left common femoral artery, and left popliteal artery. The diagnosis was performed by a blood culture positive for Capnocytophaga canimorsus. The outcome was favorable with surgery and antibiotic therapy.
- 1 June 2021
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 14, 2397-2401
Open AccessAn Infected Arterial Aneurysm and a Dog Bite: Think at Capnocytophaga canimorsus!
We describe the fourth cases of arterial aneurysm consecutive to Capnocytophaga canimorsus infection in a 77-year-old man. The infection occurred after a dog bite. He presented fever. The thoracic-abdominal computed tomography angiography revealed aneurysms on the abdominal aorta, left common femoral artery, and left popliteal artery. The diagnosis was performed by a blood culture positive for Capnocytophaga canimorsus. The outcome was favorable with surgery and antibiotic therapy.
- 1 March 2021
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 42 (6) , 633-638
18F-choline PET-computed tomography for the prediction of early treatment responses to transarterial radioembolization in patients with hepatocellular carcinoma
Background: Transarterial radioembolization (TARE) is widely used for the treatment of hepatocellular carcinoma (HCC), but early treatment response can be very difficult to assess. The aim was to evaluate 18F-fluorocholine PET/computed tomography (CT) to assess the treatment response in patients with intermediate or locally advanced HCC. Methods: Between March 2019 and July 2020, nine HCC patients treated with TARE, who underwent PET/CT at baseline and 1 month after treatment, were enrolled. The maximum, mean (SUVmean), and peak (SUVpeak) standardized uptake value (SUV), SUV normalized by lean body mass (SUL), and total lesion glycolysis (TLG) were measured. Statistical analysis used the Mann–Whitney test to evaluate the differences in parameters between responders (partial and complete response) and nonresponders (stable or progressive disease) at the 6-month follow-up, according to the modified Response Evaluation Criteria in Solid Tumors. Results: Three patients were nonresponders (progressive disease and stable disease) and six were responders. Delta SUVmean, delta SUL, and delta TLG could predict an early response (P = 0.02, P = 0.04, and P = 0.02, respectively). None of the pre-therapeutic parameters were correlated with the response. Post-therapeutic SUL, SUVmean, TLG, and SUVpeak were also predictive of the response. Conclusions: Our preliminary results showed that changes in certain metabolic parameters (from baseline PET to 1-month PET) are predictive of the response to TARE in HCC (Delta SUVmean, delta TLG, and delta SUL). The absence of post-treatment inflammation could lead to a better prediction than MRI evaluation. This study suggests that 1-month 18F-choline PET/CT could modify the clinical management predicting responders. Video http://links.lww.com/NMC/A193
- 1 March 2021
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 42 (6) , 633-638
18F-choline PET-computed tomography for the prediction of early treatment responses to transarterial radioembolization in patients with hepatocellular carcinoma
Background: Transarterial radioembolization (TARE) is widely used for the treatment of hepatocellular carcinoma (HCC), but early treatment response can be very difficult to assess. The aim was to evaluate 18F-fluorocholine PET/computed tomography (CT) to assess the treatment response in patients with intermediate or locally advanced HCC. Methods: Between March 2019 and July 2020, nine HCC patients treated with TARE, who underwent PET/CT at baseline and 1 month after treatment, were enrolled. The maximum, mean (SUVmean), and peak (SUVpeak) standardized uptake value (SUV), SUV normalized by lean body mass (SUL), and total lesion glycolysis (TLG) were measured. Statistical analysis used the Mann–Whitney test to evaluate the differences in parameters between responders (partial and complete response) and nonresponders (stable or progressive disease) at the 6-month follow-up, according to the modified Response Evaluation Criteria in Solid Tumors. Results: Three patients were nonresponders (progressive disease and stable disease) and six were responders. Delta SUVmean, delta SUL, and delta TLG could predict an early response (P = 0.02, P = 0.04, and P = 0.02, respectively). None of the pre-therapeutic parameters were correlated with the response. Post-therapeutic SUL, SUVmean, TLG, and SUVpeak were also predictive of the response. Conclusions: Our preliminary results showed that changes in certain metabolic parameters (from baseline PET to 1-month PET) are predictive of the response to TARE in HCC (Delta SUVmean, delta TLG, and delta SUL). The absence of post-treatment inflammation could lead to a better prediction than MRI evaluation. This study suggests that 1-month 18F-choline PET/CT could modify the clinical management predicting responders. Video http://links.lww.com/NMC/A193
- Open Access
- 1 August 2019
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 12, 2453-2456
An unexpected case of Bartonella alsatica prosthetic vascular graft infection
Bartonella alsatica is a wild rabbit pathogen causing bacteremia rarely reported in humans, with only three cases published so far, including one lymphadenitis and two endocarditis cases. Here, we report the case of a 66-year-old man who suffered from acute renal failure due to a membranoproliferative glomerulonephritis. Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) showed diffuse FDG uptake around the aortobifemoral graft with no indication of infection. A white blood cell scan showed an accumulation of labeled neutrophils on the left femoral part of the graft. The patient underwent surgery and an abscess around the left iliac part of the graft was found intraoperatively. Intraoperative samples were all negative, but 16S rRNA gene-based PCR was positive, and the sequence was positioned among the Bartonella species cluster. Specific PCRs targeting groEL/hsp60, rpoB and gltA genes were performed and led to the identification of B. alsatica. Accordingly, indirect immunofluorescence serological analyses were positive for Bartonella henselae and Bartonella quintana. The patient had a history of regularly hunting wild rabbits. He was treated with 100 mg of doxycycline twice a day for six months and his renal function significantly improved with no sign of persistent infection. This case highlights the contribution of serology assays and molecular-based methods in prosthetic vascular graft infection diagnosis.
- 1 August 2019
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 12, 2453-2456
Open AccessAn unexpected case of Bartonella alsatica prosthetic vascular graft infection
Bartonella alsatica is a wild rabbit pathogen causing bacteremia rarely reported in humans, with only three cases published so far, including one lymphadenitis and two endocarditis cases. Here, we report the case of a 66-year-old man who suffered from acute renal failure due to a membranoproliferative glomerulonephritis. Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) showed diffuse FDG uptake around the aortobifemoral graft with no indication of infection. A white blood cell scan showed an accumulation of labeled neutrophils on the left femoral part of the graft. The patient underwent surgery and an abscess around the left iliac part of the graft was found intraoperatively. Intraoperative samples were all negative, but 16S rRNA gene-based PCR was positive, and the sequence was positioned among the Bartonella species cluster. Specific PCRs targeting groEL/hsp60, rpoB and gltA genes were performed and led to the identification of B. alsatica. Accordingly, indirect immunofluorescence serological analyses were positive for Bartonella henselae and Bartonella quintana. The patient had a history of regularly hunting wild rabbits. He was treated with 100 mg of doxycycline twice a day for six months and his renal function significantly improved with no sign of persistent infection. This case highlights the contribution of serology assays and molecular-based methods in prosthetic vascular graft infection diagnosis.
- 1 October 2018
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 56 (4) , 562-571
Comparison of Genus Specific PCR and Culture with or without Sonication for Microbiological Diagnosis of Vascular Graft Infection
- 1 October 2018
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 56 (4) , 562-571
Comparison of Genus Specific PCR and Culture with or without Sonication for Microbiological Diagnosis of Vascular Graft Infection
- 1 November 2017
- Published by Elsevier in Médecine Nucléaire
- Vol. 41 (6) , 405-414
Fréquence de la fixation physiologique de l’uncus pancréatique en scintigraphie à l’ 111 In-pentétréotide : étude rétrospective chez 198 patients
- 1 November 2017
- Published by Elsevier in Médecine Nucléaire
- Vol. 41 (6) , 405-414
Fréquence de la fixation physiologique de l’uncus pancréatique en scintigraphie à l’ 111 In-pentétréotide : étude rétrospective chez 198 patients
- Open Access
- 9 March 2017
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (9) , 1414-1420
Role of 18F-FDG PET/CT in Posttreatment Evaluation of Anal Carcinoma
The aim of this study was to evaluate the relevance of positron emission tomography/computed tomography and 18F-fluorodeoxyglucose (FDG-PET/CT) as a strategy for response evaluation after chemoradiotherapy for anal cancer. For this, the performance of post-treatment FDG-PET/CT, the impact on patient care and the predictive value of metabolic response were assessed. Methods: This was a retrospective and multicenter analysis of 87 patients treated by chemoradiotherapy for anal squamous cell carcinoma between October 2007 and October 2013. All patients underwent systematic post-treatment FDG-PET/CT and were followed with at least a clinical examination every 4 months for 2 years, and every 6 months thereafter. Disease progression was confirmed by biopsy for all patients in case of local recurrence before surgery. Kaplan-Meier and Cox regression models were used to test for associations between metabolic or clinical endpoints and progression-free survival (PFS) or cause-specific survival (CSS). Results: Median follow-up was 25 months. FDG-PET/CT was performed 1 to 8 months (median 4 months) after completion of chemoradiotherapy. Overall, 25 patients relapsed and 13 died. The post-therapy FDG-PET/CT did not show any abnormal 18F-FDG uptake (complete metabolic response: CMR) in 55 patients whereas 32 displayed incomplete response (non-CMR): 15 patients with partial response and 17 with disease progression. Sensitivity of FDG-PET/CT for the determination of CMR was 92% (95% CI: 75-97%), specificity was 85% (95% CI: 75-92%), positive predictive value was 72% (95% CI: 61-90%), and negative predictive value was 96.4 % (95% CI: 90-98.7%). The 2-year PFS was 96% for patients with CMR, and 28% for non-CMR patients (pConclusion: FDG-PET/CT shows good accuracy in post-treatment evaluation of anal cancer and has a relevant impact on patient management. Moreover, CMR is associated with good survival outcome. Thus FDG-PET/CT may play a significant role during post-treatment follow-up of anal cancer
- 9 March 2017
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (9) , 1414-1420
Open AccessRole of 18F-FDG PET/CT in Posttreatment Evaluation of Anal Carcinoma
The aim of this study was to evaluate the relevance of positron emission tomography/computed tomography and 18F-fluorodeoxyglucose (FDG-PET/CT) as a strategy for response evaluation after chemoradiotherapy for anal cancer. For this, the performance of post-treatment FDG-PET/CT, the impact on patient care and the predictive value of metabolic response were assessed. Methods: This was a retrospective and multicenter analysis of 87 patients treated by chemoradiotherapy for anal squamous cell carcinoma between October 2007 and October 2013. All patients underwent systematic post-treatment FDG-PET/CT and were followed with at least a clinical examination every 4 months for 2 years, and every 6 months thereafter. Disease progression was confirmed by biopsy for all patients in case of local recurrence before surgery. Kaplan-Meier and Cox regression models were used to test for associations between metabolic or clinical endpoints and progression-free survival (PFS) or cause-specific survival (CSS). Results: Median follow-up was 25 months. FDG-PET/CT was performed 1 to 8 months (median 4 months) after completion of chemoradiotherapy. Overall, 25 patients relapsed and 13 died. The post-therapy FDG-PET/CT did not show any abnormal 18F-FDG uptake (complete metabolic response: CMR) in 55 patients whereas 32 displayed incomplete response (non-CMR): 15 patients with partial response and 17 with disease progression. Sensitivity of FDG-PET/CT for the determination of CMR was 92% (95% CI: 75-97%), specificity was 85% (95% CI: 75-92%), positive predictive value was 72% (95% CI: 61-90%), and negative predictive value was 96.4 % (95% CI: 90-98.7%). The 2-year PFS was 96% for patients with CMR, and 28% for non-CMR patients (pConclusion: FDG-PET/CT shows good accuracy in post-treatment evaluation of anal cancer and has a relevant impact on patient management. Moreover, CMR is associated with good survival outcome. Thus FDG-PET/CT may play a significant role during post-treatment follow-up of anal cancer
- 1 August 2015
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 29 (6) , 1321.e1-1321.e4
Should White Blood Cell Scan be Replaced by 18F-FDG PET-CT in the Diagnosis of Prosthetic Vascular Graft Infection?
- 1 August 2015
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 29 (6) , 1321.e1-1321.e4
Should White Blood Cell Scan be Replaced by 18F-FDG PET-CT in the Diagnosis of Prosthetic Vascular Graft Infection?
- 1 April 2015
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 40 (4) , e253-e254
Anthracosis Mimicking Mediastinal Lymph Node Metastases With 18F-FCholine in High-Risk Prostate Cancer
A 62-year-old patient with prostate adenocarcinoma underwent PET with radiolabeled choline (18F-Fcholine) for pretreatment staging of a high-risk prostate cancer. Images showed a significant mediastinal lymph node uptake of 18F-Fcholine. Owing to the rarity of spread to supradiaphragmatic lymph nodes, a surgical removal was performed, revealing anthracosis and no malignant cells. Even if its specificity seems better than 18F-FDG, false positives have been reported and other pathologies could mimic lymph node metastases. Consequently, histology should be performed so that the appropriate treatment can be initiated.
- 1 April 2015
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 40 (4) , e253-e254
Anthracosis Mimicking Mediastinal Lymph Node Metastases With 18F-FCholine in High-Risk Prostate Cancer
A 62-year-old patient with prostate adenocarcinoma underwent PET with radiolabeled choline (18F-Fcholine) for pretreatment staging of a high-risk prostate cancer. Images showed a significant mediastinal lymph node uptake of 18F-Fcholine. Owing to the rarity of spread to supradiaphragmatic lymph nodes, a surgical removal was performed, revealing anthracosis and no malignant cells. Even if its specificity seems better than 18F-FDG, false positives have been reported and other pathologies could mimic lymph node metastases. Consequently, histology should be performed so that the appropriate treatment can be initiated.